Lexeo Therapeutics (LXEO) Company Overview

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) --  Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006.

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:       H.C.

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at  18 months in participants with elevated LVMI at baseline

Lexeo Therapeutics, Inc. (LXEO) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

Analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) suggest a potential 57.8% increase in the stock. Although this metric has not always been accurate, the consensus among analysts in raising earnings estimates does signal a positive outlook for the stock.

Lexeo Therapeutics, Inc. anticipates releasing results from its SUNRISE-FA study using LX-2006 for FA cardiomyopathy patients in mid-2024. Results from all cohorts of the LEAD study using LX-1001 for homozygous APOE4 AD patients are expected in the second half of 2024. The global market for Alzheimer's Disease is projected to reach $9.73 billion by 2030, with an estimated 15% to 25% of AD patients carrying this allele.